Exton-based Frontage Laboratories, a contract research, development and manufacturing organization (CRDMO) offering end-to-end integrated pharmaceutical product development services, held a grand open house on May 22 to show off its newest facility.
The 46,300-square-foot good manufacturing facility expands the company’s footprint.
“For years, Frontage has been expanding by opening new sites and acquiring existing ones,” Dr. Wentao Zhang, Frontage Laboratories co-CEO, said. “The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs.”
Expansion will reinforce the company’s commitment to accelerating pharmaceutical and biotech innovation. The facility includes two formulation development labs, two high-potent suites, two aseptic suites, three analytical labs, and five non-sterile suites. The facility will cover all aspects of clinical supplies such as analytical testing, formulation development, manufacturing, packaging, labelling, distribution, and storage.
In addition, expansion will complement Frontage’s existing service offerings including drug substance synthesis, safety and toxicology studies, and clinical trial support.
Frontage Laboratories is a wholly owned subsidiary of Frontage Holdings Corp., a CRDMO from drug discovery through late-phase clinical trials and manufacturing. Frontage serves pharmaceutical and biotech companies. It operates 26 sites worldwide.